Cord blood stem cells are currently approved only for hematopoietic reconstitution, however numerous experimental uses are being reported. Given that cord blood stem cells have been reported to possess pluripotent characteristics, a wide variety of new indications are being developed. For...
Division of most mammalian cells is accompanied by reduction in the length of telomeres, which is responsible in part for cellular senescence and death. Some cells, particularly stem cells and cancer cells, express the enzyme telomerase and are not restricted by the "Hayflick Limit". Some data exists to support the concept...
The current patent covers a cosmetic generated using a variant of stromal derived factor (SDF-1) which the inventors termed stem cell active factor (SCAF). The natural function of SDF-1 is to call in stem cells to injured tissue, for example, after a heart attack there is a surge of SDF-1 which is involved in mediating mobilization of stem cells from the bone... The current patent covers a device useful for detecting chemicals in a patient, with the device being implantable. Practically the device claimed is used for implantation into the heart and provides information via electrical signals as to the chemical environment based on changes to the "biosensing" cells. In its first claim, the patent covers "a biosensor... Mesenchymal stem cells are known to possess a variety of immune modulatory activities such as suppression of allogeneic responses, as well as induction of T regulatory cells. Mechanisms include expression of IDO and HLA-G. Mesenchymal stem cells have been demonstrated effective in patients with... One of the problems with cell therapy after injury is the possibility of accelerating scar tissue formation. The current patent teaches the use of X-rays, administered by parallel micro-beams at doseages that are sufficient to remove inhibitors of regeneration.
The patent also discloses the use of exogenous stem cells in combination with the X-rays in order to accelerate healing.
It has always been the belief of StemCellPatents.com that the future of stem cell therapeutics is not only in the development and use of stem cell types, but the integration of stem cells with other modalities to attain synergy. For example, while FDA/EMEA development of cellular product candidates takes years and hundreds of millions of dollars, the same, or very... The issued claim in the current patent covers a method of diagnosing a motor neuron disease based on sequences associated with mutations in the neuropathy target esterase (NTE) gene. If one reads the specification, descriptions of treatments based on inhibiting expression of the mutated NTE gene using techniques such as siRNA are disclosed. Genetic complementation using stem cells are also... Vascular aneurysms are thinning of blood vessel walls, which is usually associated with vessel trauma, non-specific degeneration, atherosclerosis, or infection. The term "aneurysm" comes from the Latin "aneurysma" which means "dilation". Aneurysms are hazardous because of the potential to burst. They are usually prevelant in the aorta or cerebral arteries.
The current patent provides... Many diseases are associated with either too much apoptosis (eg ALS, Parkinson's, Liver failure, etc) or too little apoptosis (cancer). The current patent covers a method to suppress apoptosis in mammalian cells. The method consists of transfecting an isolated population bone marrow derived stromal cells (either autologous or allogeneic) with a nucleic acid encoding the...
Implantable cell/tissue-based biosensing device
Patent Number: 7,519,409
Stromal antigen-presenting cells and use thereof
Patent Number: 7,553,661
Methods for assisting recovery of damaged brain and spinal cord using arrays of X-ray microplanar beams
Patent Number: 7,158,607
Methods for assisting recovery of damaged brain and spinal cord using arrays of X-Ray microplanar beams
Patent Number: 7,305,064
Compositions and methods for detecting and treating motor neuron disorders
Patent Number: 7,384,748
Compositions, systems and methods for treatment of defects in blood vessels
Patent Number: 7,201,918
Clusterin-mediated inhibition of apoptosis via stromal bone marrow cell delivery to a cardiac site
Patent Number: 7,524,490